CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 17 enrolled
Drug / intervention
Curcumin +1 moredrug
Likely dose
Curcumin 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03085680
NCT03085680Phase 3Completed

Does Dietary Supplementation With Curcumin Maintain or Improve Physical and Cognitive Function in Aging Adults at Increased Risk for Disability?

University of Florida·interventional·Posted Mar 21, 2017·Updated Jul 26, 2022

In Brief

A Phase 3 clinical trial evaluating Curcumin and microcrystalline cellulose for Older Adults and 2 related conditions. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This placebo-controlled RCT tests whether dietary supplementation with curcumin maintains or improves cognitive and physical function in older adults who are at high risk of functional decline due existing (mild) functional impairments and elevated biomarkers of inflammation and explore the association between functional changes and changes in biological indicators of active inflammation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 21, 2017
Enrollment StartAug 11, 2017
Primary CompletionOct 18, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.3 years ago

Interventions

Curcumindrug

Participants will be given curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.

microcrystalline cellulosedrug

Participants will be instructed to consume two capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.